All In Biotech

Free tool

FAERS Monitor: Pyrukynd

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216196 or its brand name (Pyrukynd, Mitapivat Sulfate). Reports on generic versions are filed under their own applications.

Reports

1,331

Serious

199

15% of reports

Hospitalization

109

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • haemoglobin decreased230
  • product dose omission issue197
  • headache173
  • fatigue159
  • insomnia124
  • off label use123
  • nausea86
  • arthralgia82
  • drug ineffective76
  • back pain64
  • dizziness56
  • asthenia52
  • malaise51
  • product dose omission in error51
  • pain47

Reports by year received

View as table
YearReports
2022119
2023182
2024192
2025217
2026621

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,828 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haemoglobin decreasedSignal23035.531.57,691
product dose omission in errorSignal5128.521.81,326
product dose omission issueSignal19710.69.31,725
insomniaSignal1247.46.2683
headacheSignal1734.43.8458
back painSignal644.43.4164
fatigueSignal1593.22.8252
arthralgiaSignal823.12.5118
off label useSignal1232.21.985
astheniaSignal522.21.733
malaise511.81.419
dizziness561.81.419
nausea861.71.426
pain471.20.92
drug ineffective760.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.